Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · SLNO · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
7
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Soleno Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
SLNO insider buying and selling by quarter
SLNO insider selling · SLNO insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · SLNO ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
SLNO executive sell shares · SLNO board member insider trading · SLNO insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 18, 2026 | Yen Kristen SEE REMARKS | Other | 37,639 | — | Form 4 |
| May 18, 2026 | Volck Birgitte Director | Other | 17,536 | — | Form 4 |
| May 18, 2026 | Sinclair Andrew Director | Other | 10,491 | — | Form 4 |
| May 18, 2026 | Pauls Matthew Director | Other | 10,491 | — | Form 4 |
| May 18, 2026 | Norrett Kevin Chief Business Officer | Other | 17,786 | — | Form 4 |
| May 18, 2026 | Manning Meredith Chief Commercial Officer | Other | 64,507 | — | Form 4 |
| May 18, 2026 | Joshi Manher Chief Development Officer | Other | 20,171 | — | Form 4 |
| May 18, 2026 | Huang Michael F. Sr. VP of Clinical Development | Other | 39,823 | — | Form 4 |
| May 18, 2026 | Hirano Patricia C SEE REMARKS | Other | 22,702 | — | Form 4 |
| May 18, 2026 | Hahn Mark W Director | Other | 10,046 | — | Form 4 |
| May 18, 2026 | Fulk Jennifer CHIEF FINANCIAL OFFICER | Other | 39,200 | — | Form 4 |
| May 18, 2026 | Bir Dawn Carter Director | Other | 16,991 | — | Form 4 |
| May 18, 2026 | Anish Bhatnagar CHIEF EXECUTIVE OFFICER · Director | Other | 583,656 | — | Form 4 |
| Mar 27, 2026 | Manning Meredith Chief Commercial Officer | Sale | 4,864 | $146K | Form 4 |
| Mar 27, 2026 | Manning Meredith Chief Commercial Officer | Sale | 2,100 | $65K | Form 4 |
| Mar 27, 2026 | Manning Meredith Chief Commercial Officer | Sale | 558 | $18K | Form 4 |
| Mar 27, 2026 | Huang Michael F. Sr. VP of Clinical Development | Sale | 4,256 | $128K | Form 4 |
| Mar 27, 2026 | Huang Michael F. Sr. VP of Clinical Development | Sale | 1,838 | $57K | Form 4 |
| Mar 27, 2026 | Huang Michael F. Sr. VP of Clinical Development | Sale | 488 | $15K | Form 4 |
| Mar 2, 2026 | Fulk Jennifer CHIEF FINANCIAL OFFICER | Award | 39,200 | — | Form 4 |
| Jan 21, 2026 | Yen Kristen SEE REMARKS | Award | 10,400 | — | Form 4 |
| Jan 21, 2026 | Norrett Kevin Chief Business Officer | Award | 3,500 | — | Form 4 |
| Jan 21, 2026 | Manning Meredith Chief Commercial Officer | Award | 28,600 | — | Form 4 |
| Jan 21, 2026 | Mackaness James H CHIEF FINANCIAL OFFICER | Award | 28,600 | — | Form 4 |
| Jan 21, 2026 | Joshi Manher Chief Development Officer | Award | 4,100 | — | Form 4 |
Manning Meredith
Chief Commercial Officer
Date
May 18
Shares
64,507
Price
—
Value
—
Huang Michael F.
Sr. VP of Clinical Development
Date
May 18
Shares
39,823
Price
—
Value
—
Anish Bhatnagar
CHIEF EXECUTIVE OFFICER · Director
Date
May 18
Shares
583,656
Price
—
Value
—
Manning Meredith
Chief Commercial Officer
Date
Mar 27
Shares
4,864
Price
$30.04
Value
$146K
Manning Meredith
Chief Commercial Officer
Date
Mar 27
Shares
2,100
Price
$31.04
Value
$65K
Manning Meredith
Chief Commercial Officer
Date
Mar 27
Shares
558
Price
$31.72
Value
$18K
Huang Michael F.
Sr. VP of Clinical Development
Date
Mar 27
Shares
4,256
Price
$30.04
Value
$128K
Huang Michael F.
Sr. VP of Clinical Development
Date
Mar 27
Shares
1,838
Price
$31.04
Value
$57K
Huang Michael F.
Sr. VP of Clinical Development
Date
Mar 27
Shares
488
Price
$31.72
Value
$15K
Manning Meredith
Chief Commercial Officer
Date
Jan 21
Shares
28,600
Price
—
Value
—
Mackaness James H
CHIEF FINANCIAL OFFICER
Date
Jan 21
Shares
28,600
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About SLNO insider trading
SLNO insider trades
Soleno Therapeutics, Inc. (SLNO) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Manning Meredith (Chief Commercial Officer), Huang Michael F. (Sr. VP of Clinical Development), Yen Kristen (SEE REMARKS). Over the past 12 months, 5 insiders have filed transactions with the SEC. SLNO insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Soleno Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
SLNO insider trading · 5 questionsThe insiders of Soleno Therapeutics, Inc. (SLNO) include executives and directors such as Manning Meredith (Chief Commercial Officer), Huang Michael F. (Sr. VP of Clinical Development), Yen Kristen (SEE REMARKS), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026